196 related articles for article (PubMed ID: 17184669)
1. Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era.
De Pas TM; de Braud F; Catalano G; Putzu C; Veronesi G; Leo F; Solli PG; Brambilla D; Paganelli G; Spaggiari L
Ann Thorac Surg; 2007 Jan; 83(1):231-4. PubMed ID: 17184669
[TBL] [Abstract][Full Text] [Related]
2. The clinical stage of non-small cell lung cancer as assessed by means of fluorodeoxyglucose-positron emission tomographic/computed tomographic scanning is less accurate in cigarette smokers.
Bryant AS; Cerfolio RJ
J Thorac Cardiovasc Surg; 2006 Dec; 132(6):1363-8. PubMed ID: 17140957
[TBL] [Abstract][Full Text] [Related]
3. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3.
Lee BE; Redwine J; Foster C; Abella E; Lown T; Lau D; Follette D
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):615-9. PubMed ID: 18329480
[TBL] [Abstract][Full Text] [Related]
4. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?
Cerfolio RJ; Bryant AS
Ann Thorac Surg; 2007 Oct; 84(4):1092-7. PubMed ID: 17888953
[TBL] [Abstract][Full Text] [Related]
5. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer.
Lardinois D; Weder W; Roudas M; von Schulthess GK; Tutic M; Moch H; Stahel RA; Steinert HC
J Clin Oncol; 2005 Oct; 23(28):6846-53. PubMed ID: 16192576
[TBL] [Abstract][Full Text] [Related]
6. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.
Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA
J Thorac Cardiovasc Surg; 2005 Jul; 130(1):151-9. PubMed ID: 15999056
[TBL] [Abstract][Full Text] [Related]
7. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy.
Dehing-Oberije C; De Ruysscher D; van der Weide H; Hochstenbag M; Bootsma G; Geraedts W; Pitz C; Simons J; Teule J; Rahmy A; Thimister P; Steck H; Lambin P
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1039-44. PubMed ID: 17889446
[TBL] [Abstract][Full Text] [Related]
8. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer.
Downey RJ; Akhurst T; Gonen M; Park B; Rusch V
J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1419-27. PubMed ID: 17532932
[TBL] [Abstract][Full Text] [Related]
9. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Scheiderbauer J; Budach W; Kotzerke J; Bares R
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer.
Patz EF; Connolly J; Herndon J
AJR Am J Roentgenol; 2000 Mar; 174(3):769-74. PubMed ID: 10701623
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less.
Port JL; Andrade RS; Levin MA; Korst RJ; Lee PC; Becker DE; Altorki NK
J Thorac Cardiovasc Surg; 2005 Dec; 130(6):1611-5. PubMed ID: 16308006
[TBL] [Abstract][Full Text] [Related]
12. Definitive chemoradiation therapy following surgical resection or radiosurgery plus whole-brain radiation therapy in non-small cell lung cancer patients with synchronous solitary brain metastasis: a curative approach.
Parlak C; Mertsoylu H; Güler OC; Onal C; Topkan E
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):885-91. PubMed ID: 24495594
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
[TBL] [Abstract][Full Text] [Related]
14. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment of non-small cell lung cancer with synchronous brain metastases: a single center experience.
Melloni G; Bandiera A; Gregorc V; Carretta A; Ciriaco P; Viganò M; Franzin A; Bolognesi A; Picozzi P; Zannini P
J Cardiovasc Surg (Torino); 2011 Aug; 52(4):613-9. PubMed ID: 21792167
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.
Kong FM; Frey KA; Quint LE; Ten Haken RK; Hayman JA; Kessler M; Chetty IJ; Normolle D; Eisbruch A; Lawrence TS
J Clin Oncol; 2007 Jul; 25(21):3116-23. PubMed ID: 17634490
[TBL] [Abstract][Full Text] [Related]
17. Overestimation of the prognostic significance of SUV measurement by positron emission tomography for non-small-cell lung cancer.
Atkins CD
J Clin Oncol; 2005 Sep; 23(27):6799-800; author reply 6800. PubMed ID: 16170191
[No Abstract] [Full Text] [Related]
18. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
[TBL] [Abstract][Full Text] [Related]
19. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer.
Reed CE; Harpole DH; Posther KE; Woolson SL; Downey RJ; Meyers BF; Heelan RT; MacApinlac HA; Jung SH; Silvestri GA; Siegel BA; Rusch VW;
J Thorac Cardiovasc Surg; 2003 Dec; 126(6):1943-51. PubMed ID: 14688710
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
